01921nas a2200277   4500000000100000008004100001260001200042653002000054653001400074653002100088653002100109100001500130700001100145700001300156700001300169700001300182700001300195700001200208700001300220245012700233856011900360300001200479490000800491520113000499022001401629       2019                            d  c10/201910aVenomous snakes10asnakebite10aAnti-snake venom10aAnnual incidence1 aGajbhiye R1 aKhan S1 aKokate P1 aMashal I1 aKharat S1 aBodade S1 aYadav A1 aMahale S00aIncidence & management practices of snakebite: A retrospective study at Sub-District Hospital, Dahanu, Maharashtra, India.  uhttp://www.ijmr.org.in/article.asp?issn=0971-5916;year=2019;volume=150;issue=4;spage=412;epage=416;aulast=Gajbhiye  a412-4160 v1503 a<p>This study was undertaken to know the incidence and management practices of snakebite envenomation at the First Referral Unit - Sub-District Hospital, Dahanu, Maharashtra, India. Retrospective analysis of snakebite case records (n=145) was carried out for one-year period (January to December 2014). The annual incidence of snakebite was 36 per 100,000 population with case fatality rate of 4.5 per cent. Venomous snakebites were 76 per cent and non-venomous snakebites were 24 per cent. Overall, snakebites were more common in males (52.4%) than females (47.6%). Majority of the snakebites (66%) were in the age group of 18-45 yr. Seasonal variation was observed with highest snakebites in monsoon (58%). Lower extremities were the most common site of bites (63%). Neurotoxic and vasculotoxic envenomation were reported in 19 and 27 per cent snakebite cases, respectively. Anti-snake venom (ASV) was administered at an average dose of 7.5±0.63 vials (range 2-40, median 6). There was no uniform protocol followed for ASV administration as per the National Snakebite Management Protocol of Government of India (2009).</p>  a0971-5916